



ASX Announcement

4 June 2019

## Release of Shares from Voluntary Escrow

**Creso Pharma Limited** (ASX: "CPH", the "Company" or "Creso") advises in accordance with Listing Rule 3.10A, that 2,053,026 fully paid ordinary shares ("Shares") and 303,027 Performance Shares will be released from voluntary escrow on Thursday, 20 June 2019.

The securities to be released from voluntary escrow are comprised of:

- a) 2,053,026 Shares of the 8,212,121 Shares issued to the vendors of Kunna Canada Ltd upon the completion of the Company's recent acquisition of Kunna Canada Ltd on 20 December 2018; and
- b) 303,027 Performance Shares of the 1,212,120 Performance Shares issued to the vendors of Kunna Canada Ltd subject to vesting conditions.

The Company applied for, and was subsequently granted, quotation of the Shares on 20 December 2018. Holding locks applicable to the abovementioned shares will be lifted prior to the commencement of trade on Thursday, 20 June 2019.

Following the expiry of escrow restrictions on the above securities, the following securities of the Company will remain subject to escrow restrictions:

- 2,053,027 Shares, escrowed to 20 September 2019;
- 303,027 Performance Shares, escrowed to 20 September 2019;
- 2,053,043 Shares, escrowed to 20 December 2019; and
- 303,039 Performance Shares, escrowed to 20 December 2019.

### Corporate Enquiries:

EverBlu Capital  
Level 39, Aurora Place  
88 Phillip Street, Sydney NSW 2000  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 000



### **About Creso Pharma Ltd**

([www.cresopharma.com](http://www.cresopharma.com))

Creso brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.